A citation-based method for searching scientific literature

Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, Shona Clegg, Casper Nielsen, Nick C Fox, David Wilkie, Jennifer M Nicholas, Virginia L Calder, John Greenwood, Chris Frost, Richard Nicholas. Lancet 2014
Times Cited: 240







List of co-cited articles
1038 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
725
31

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
320
22

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Fred Lublin, David H Miller, Mark S Freedman, Bruce A C Cree, Jerry S Wolinsky, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard M J Uitdehaag,[...]. Lancet 2016
228
21

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Sèze, Marc Debouverie, Olivier Gout, Pierre Clavelou,[...]. Mult Scler 2016
176
19

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Robert J Fox, Christopher S Coffey, Robin Conwit, Merit E Cudkowicz, Trevis Gleason, Andrew Goodman, Eric C Klawiter, Kazuko Matsuda, Michelle McGovern, Robert T Naismith,[...]. N Engl J Med 2018
100
19

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman,[...]. Lancet Neurol 2018
119
17

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
16

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Sawsan Youssef, Olaf Stüve, Juan C Patarroyo, Pedro J Ruiz, Jennifer L Radosevich, Eun Mi Hur, Manuel Bravo, Dennis J Mitchell, Raymond A Sobel, Lawrence Steinman,[...]. Nature 2002
867
16

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg,[...]. Lancet Neurol 2011
82
19

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
Dennis Chan, Sophie Binks, Jennifer M Nicholas, Chris Frost, M Jorge Cardoso, Sebastien Ourselin, David Wilkie, Richard Nicholas, Jeremy Chataway. Lancet Neurol 2017
52
30


Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
15

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Chris H Polman, Stephen C Reingold, Brenda Banwell, Michel Clanet, Jeffrey A Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdova, Michael Hutchinson, Ludwig Kappos,[...]. Ann Neurol 2011
14

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Raju Kapoor, Julian Furby, Thomas Hayton, Kenneth J Smith, Daniel R Altmann, Robert Brenner, Jeremy Chataway, Richard A C Hughes, David H Miller. Lancet Neurol 2010
169
14

Pathological mechanisms in progressive multiple sclerosis.
Don H Mahad, Bruce D Trapp, Hans Lassmann. Lancet Neurol 2015
558
13

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,[...]. Ann Neurol 2009
545
12

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
673
12

Statin treatment in multiple sclerosis: a systematic review and meta-analysis.
Gorm Pihl-Jensen, Anna Tsakiri, Jette Lautrup Frederiksen. CNS Drugs 2015
46
26

Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Timothy Vollmer, Lyndon Key, Valerie Durkalski, William Tyor, John Corboy, Silva Markovic-Plese, Jana Preiningerova, Marco Rizzo, Inderjit Singh. Lancet 2004
367
11

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Ari J Green, Jeffrey M Gelfand, Bruce A Cree, Carolyn Bevan, W John Boscardin, Feng Mei, Justin Inman, Sam Arnow, Michael Devereux, Aya Abounasr,[...]. Lancet 2017
180
11

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.
Rebecca Spain, Katherine Powers, Charles Murchison, Elizabeth Heriza, Kimberly Winges, Vijayshree Yadav, Michelle Cameron, Ed Kim, Fay Horak, Jack Simon,[...]. Neurol Neuroimmunol Neuroinflamm 2017
57
19

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco,[...]. Lancet Neurol 2020
36
30

Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.
Bianca Weinstock-Guttman, Robert Zivadinov, Naeem Mahfooz, Ellen Carl, Allison Drake, Jaclyn Schneider, Barbara Teter, Sara Hussein, Bijal Mehta, Marc Weiskopf,[...]. J Neuroinflammation 2011
124
10

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Jerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, Patricia K Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani. Ann Neurol 2007
273
10

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Feng Mei, Stephen P J Fancy, Yun-An A Shen, Jianqin Niu, Chao Zhao, Bryan Presley, Edna Miao, Seonok Lee, Sonia R Mayoral, Stephanie A Redmond,[...]. Nat Med 2014
293
10

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
9

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Hillel Panitch, Aaron Miller, Donald Paty, Brian Weinshenker. Neurology 2004
288
9

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch,[...]. N Engl J Med 2010
465
9

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, Maria Trojano, Maria Pia Amato, Maria G Marrosu, Ada Francia, Ciro Florio, Giuseppe Orefice, Gioacchino Tedeschi,[...]. Mult Scler 2016
15
60

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.
Stephen M Smith, Yongyue Zhang, Mark Jenkinson, Jacqueline Chen, P M Matthews, Antonio Federico, Nicola De Stefano. Neuroimage 2002
9

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
722
9

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
Caryl J Schwartzbach, Richard A Grove, Robert Brown, Debra Tompson, Florian Then Bergh, Douglas L Arnold. J Neurol 2017
51
17

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Daniel Ontaneda, Robert J Fox, Jeremy Chataway. Lancet Neurol 2015
132
9

Regenerating CNS myelin - from mechanisms to experimental medicines.
Robin J M Franklin, Charles Ffrench-Constant. Nat Rev Neurosci 2017
206
9

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
Diego Cadavid, Laura Balcer, Steven Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo Vanopdenbosch, Jette Frederiksen, Mark Skeen, Glenn J Jaffe, Helmut Butzkueven,[...]. Lancet Neurol 2017
132
9

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
686
9

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
W I McDonald, A Compston, G Edan, D Goodkin, H P Hartung, F D Lublin, H F McFarland, D W Paty, C H Polman, S C Reingold,[...]. Ann Neurol 2001
8

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.
R A Marrie, R Rudick, R Horwitz, G Cutter, T Tyry, D Campagnolo, T Vollmer. Neurology 2010
233
8

An adverse lipid profile is associated with disability and progression in disability, in people with MS.
Prudence Tettey, Steve Simpson, Bruce Taylor, Leigh Blizzard, Anne-Louise Ponsonby, Terence Dwyer, Karam Kostner, Ingrid van der Mei. Mult Scler 2014
72
11

Progressive multiple sclerosis: pathology and pathogenesis.
Hans Lassmann, Jack van Horssen, Don Mahad. Nat Rev Neurol 2012
514
8

Evidence for a two-stage disability progression in multiple sclerosis.
Emmanuelle Leray, Jacqueline Yaouanq, Emmanuelle Le Page, Marc Coustans, David Laplaud, Joël Oger, Gilles Edan. Brain 2010
342
8

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.
John Greenwood, Lawrence Steinman, Scott S Zamvil. Nat Rev Immunol 2006
453
8

Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination.
Zita Hubler, Dharmaraja Allimuthu, Ilya Bederman, Matthew S Elitt, Mayur Madhavan, Kevin C Allan, H Elizabeth Shick, Eric Garrison, Molly T Karl, Daniel C Factor,[...]. Nature 2018
87
9

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Mansoureh Togha, Sanaz Ahmadi Karvigh, Masoud Nabavi, Nahid Beladi Moghadam, Mohammad Hossein Harirchian, Mohammad Ali Sahraian, Anahita Enzevaei, Alireza Nourian, Hossein Ghanaati, Kavous Firouznia,[...]. Mult Scler 2010
56
14

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
Bianca Weinstock-Guttman, Robert Zivadinov, Dana Horakova, Eva Havrdova, Jun Qu, Grace Shyh, Elizabeth Lakota, Kerri O'Connor, Darlene Badgett, Miriam Tamaño-Blanco,[...]. J Neurol Neurosurg Psychiatry 2013
76
9

Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.
Simon Zhornitsky, Kyla A McKay, Luanne M Metz, Charlotte E Teunissen, Manu Rangachari. Mult Scler Relat Disord 2016
42
16

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Roberta Lanzillo, Giuseppe Orefice, Mario Quarantelli, Carlo Rinaldi, Anna Prinster, Gianluca Ventrella, Daniele Spitaleri, Giacomo Lus, Giovanni Vacca, Barbara Carotenuto,[...]. Mult Scler 2010
57
12

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H Polman, Stephen C Reingold, Gilles Edan, Massimo Filippi, Hans-Peter Hartung, Ludwig Kappos, Fred D Lublin, Luanne M Metz, Henry F McFarland, Paul W O'Connor,[...]. Ann Neurol 2005
7

Axonal transection in the lesions of multiple sclerosis.
B D Trapp, J Peterson, R M Ransohoff, R Rudick, S Mörk, L Bö. N Engl J Med 1998
7

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.
N De Stefano, A Giorgio, M Battaglini, M Rovaris, M P Sormani, F Barkhof, T Korteweg, C Enzinger, F Fazekas, M Calabrese,[...]. Neurology 2010
198
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.